Anixa Biosciences, Inc. - Common Stock (ANIX)
4.3900
-0.2100 (-4.57%)
NASDAQ · Last Trade: Nov 12th, 6:27 PM EST

RALEIGH, NC / ACCESSWIRE / December 6, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Winter Conference" is taking place on December 10-11, 2024.
Via ACCESSWIRE · December 6, 2024
Anixa Biosciences, Inc. (NASDAQ: ANIX) Featured in Coverage of the EF Hutton Annual Global Conference
Anixa Biosciences (NASDAQ: ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. For more information, visit the company’s website at www.anixa.com .
Via Investor Brand Network · May 16, 2024

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Via ACCESSWIRE · May 7, 2024
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
2023 witnessed a remarkable flurry of activity in the biopharmaceutical industry, with several high-profile acquisitions underscoring the sector's dynamic nature and its relentless pursuit of innovation. Here’s a look at some of the most significant deals that not only made headlines but are set to reshape the therapeutic landscape.
Via AB Newswire · March 20, 2024

NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 17-18, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Via ACCESSWIRE · January 15, 2024

SAN JOSE, CA / ACCESSWIRE / August 10, 2023 / Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the human immune system has led to the development of innovative immuno-therapy drugs that have been approved and commercialized.
Via ACCESSWIRE · August 10, 2023